Sequential intravesical gemcitabine–docetaxel after BCG failure non-muscle invasive bladder cancer: Oncological outcomes and safety profile. // The French Journal of Urology. – URL: https://www.sciencedirect.com/science/article/pii/S2950393026001609?dgcid=rss_sd_all
Sequential intravesical gemcitabine–docetaxel after BCG failure non-muscle invasive bladder cancer: Oncological outcomes and safety profile. The French Journal of Urology. https://www.sciencedirect.com/science/article/pii/S2950393026001609?dgcid=rss_sd_all
“Sequential intravesical gemcitabine–docetaxel after BCG failure non-muscle invasive bladder cancer: Oncological outcomes and safety profile.” The French Journal of Urology.
@article{article67765,
title = {Sequential intravesical gemcitabine–docetaxel after BCG failure non-muscle invasive bladder cancer: Oncological outcomes and safety profile},
journal = {The French Journal of Urology},
url = {https://www.sciencedirect.com/science/article/pii/S2950393026001609?dgcid=rss_sd_all}
}
Objective To assess prostate‐specific antigen (PSA) testing according to income, age, and region of residence in Sweden. Patients and Methods We conducted a nationwide, population‐based open cohort study of men aged 40–90 years in...